Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348918 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
A Phase 2 study, sponsored by Allegro Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
NCT02348918 is a Phase 2 study that has completed, run by Allegro Ophthalmics. The registered enrollment target is 218 participants.
The verdict
NCT02348918, a Phase 2 study, has completed, sponsored by Allegro Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
Study Summary
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
Interventions
- DRUG Avastin
- DRUG Luminate 1.0mg
- DRUG Luminate 2.0mg
- DRUG Luminate 3.0mg
- DRUG Luminate 0.5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2017-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348918
The ClinicalTrials.gov registry entry for NCT02348918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegro Ophthalmics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Avastin is the first listed.
NCT02348918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348918 about?
NCT02348918 is a clinical study titled "Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema". A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
What is the current status of trial NCT02348918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2014-10-13. Estimated completion is 2017-06-13.
What interventions are being tested in trial NCT02348918?
The interventions under investigation include: Avastin (DRUG), Luminate 1.0mg (DRUG), Luminate 2.0mg (DRUG), Luminate 3.0mg (DRUG), Luminate 0.5mg (DRUG).
Who is sponsoring clinical trial NCT02348918?
This trial is sponsored by Allegro Ophthalmics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.